Info
Dialog
Download

Bewertung Bewertungen

Beschreibung:

RTOG 0825 Phase III GBM Salvage Treatment Summary Form (SF) Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5AE2A23C-8AF1-6A8B-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5AE2A23C-8AF1-6A8B-E044-0003BA3F9857

Stichworte:

Hirntumoren

Klinische Studie [Dokumenttyp]

Treatment Form

Zentralnervensystemtumoren

Versionen (4)

26.08.12 26.08.12 -
09.01.15 09.01.15 - Martin Dugas
09.01.15 09.01.15 - Martin Dugas
09.01.15 09.01.15 - Martin Dugas

Hochgeladen am:

9. Januar 2015

DOI:

Für eine Beantragung loggen Sie sich ein.

Lizenz :

Creative Commons BY-NC 3.0 Legacy

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Brain and Central Nervous System Tumors NCT00884741 Treatment - RTOG 0825 Phase III GBM Salvage Treatment Summary Form (SF) - 2797440v1.0

Englisch 1

Englisch

Details

INSTRUCTIONS: Submit this form at the completion of each cycle of salvage treatment. Dates are to be recorded as mm-dd-yyyy unless otherwise specified

1 Formulare

StudyEvent: RTOG 0825 Phase III GBM Salvage Treatment Summary Form (SF)
1. INSTRUCTIONS: Submit this form at the completion of each cycle of salvage treatment. Dates are to be recorded as mm-dd-yyyy unless otherwise specified

Module 1

RTOG Study No.

Case #

Institution Name

Institution No.

Patient Initials

RTOG Patient ID

Amended Data (INSTRUCTIONS: Complete form on web to unblind the protocol treatment arm)

Yes

Assessment

Height (CM)

Weight (CM)

BSA (M2)

Karnofsky Performance Status (Use 9 if unknown)

Dead (0)

Moribund, Fatal Processes Progressing Rapidly (10)

Normal, No Complaints, No Evidence Of Disease (100)

Very Sick, Hospitalization Indicated. Death Not Imminent (20)

7 weitere Items in der Detailansicht.

Neurologic function

Minor Neurologic Symptoms, Fully Active At Home/work Without Assistance (Minor neurologic symptoms, fully active at home/work without assistance)

Moderate Neurologic Symptoms, Fully Active At Home/work But Requires Assistance (Moderate neurologic symptoms, fully active at home/work but requires assistance)

Moderate Neurologic Symptoms, Less Than Fully Active At Home/work And Requires Assitance (Moderate neurologic symptoms, less than fully active at home/work and requires assistance)

No Neurologic Symptoms, Fully Active At Home/work Without Assistance (No neurologic symptoms, fully active at home/work without assistance)

Severe Neurologic Symptoms, Totally Inactive Requiring Complete Assistance At Home Or Institution, Unable To Work (Severe neurologic symptoms, totally inactive requiring complete assistance at home or institution, unable to work)

Unknown (Unknown)

Disease Progression

Salvage treatment being reported

Bevacizumab Alone (Bevacizumab alone)

Bevacizumab And Irinotecan (Bevacizumab and Irinotecan)

Bevacizumab And Tmz Salvage (Bevacizumab and TMZ salvage)

Is protocol chemotherapy continuing?

Yes

Unnamed 3

Agent Name

Agent Start Date (MM DD YYYY)

Agent End Date (MM DD YYYY)

Agent Total Dose (MG)

Total number of doses

Was dose reduced more than 20%

Yes

Reason for Treatment Modification

Adverse Event/side Effects/complications (Adverse event/side effects/complications)

Alternative Therapy (Alternative therapy)

Death On Study (Death on study)

Disease Progression, Relapse During Active Treatment (Disease progression, relapse during active treatment)

4 weitere Items in der Detailansicht.

Reason Treatment Ended

Adverse Event/side Effects/complications (Adverse Event/Side Effects/Complications)

Alternative Therapy (Alternative therapy)

Death On Study (Death on study)

Disease Progression, Relapse During Active Treatment (Disease progression, relapse during active treatment)

5 weitere Items in der Detailansicht.

Alternative therapy, specify

Other specify

Protocol Specific Adverse Event Evaluation

Were there any hemorrhage events during this report period

Yes

MedDRA Code

CTC Adverse Event Term

CTC AE Grade

CTCAE Begin Date (MM DD YYYY)

CTC AE Attribution Code

Definite (Definite)

Possible (Possible)

Probable (Probable)

Unlikely (Unlikely)

Unrelated (Unrelated)

CTC AE Attribution Code

Definite (Definite)

Possible (Possible)

Probable (Probable)

Unlikely (Unlikely)

Unrelated (Unrelated)

SAE report submitted

No (No)

Unknown (Unknown)

Yes (Yes)

SAE report submitted

No (No)

Unknown (Unknown)

Yes (Yes)

INR (International Normalized Ratio of prothrombin time Value)

INR LLN (Institution)

INR ULN (Institution)

PTT (sec) (Partial Thromboplastin Time Value)

PTT LLN (Institution)

seconds

PTT ULN (Institution)

seconds

PT (Prothrombin Time Value)

seconds

PT LLN (Institution)

seconds

PT ULN (Institution)

seconds

Platelets (PLT) (Platelets x 1000 cmm Value)

1000/uL

PLT LLN (Institution)

PLT ULN (Institution)

Date (MM DD YYYY)

Protocol Specific Adverse Event Evaluation

Were there any study-specific adverse events during this report period

Yes

CTC Adverse Event Term

CTC AE Grade

CTCAE Begin Date (MM DD YYYY)

CTC AE Attribution Code

Definite (Definite)

Possible (Possible)

Probable (Probable)

Unlikely (Unlikely)

Unrelated (Unrelated)

SAE report submitted

No (No)

Unknown (Unknown)

Yes (Yes)

Protocol Specific Adverse Event Evaluation

Any Treatment Related Adverse Events

No (No)

Unknown (Unknown)

Yes (Yes)

MedDRA Code

CTC Adverse Event Term

CTC AE Grade

CTCAE Begin Date (MM DD YYYY)

CTC AE Attribution Code

Definite (Definite)

Possible (Possible)

Probable (Probable)

Unlikely (Unlikely)

Unrelated (Unrelated)

SAE report submitted

No (No)

Unknown (Unknown)

Yes (Yes)

Footer Module

Comments

Signature of Person Completing This Form

Form Completion Date, Original

Zum Seitenanfang zurückkehren

Beschreibung:

Link:

Stichworte:

Versionen (4)

Hochgeladen am:

DOI:

Lizenz :

Modell Kommentare :

Itemgroup Kommentare für :

Item Kommentare für :

Brain and Central Nervous System Tumors NCT00884741 Treatment - RTOG 0825 Phase III GBM Salvage Treatment Summary Form (SF) - 2797440v1.0

INSTRUCTIONS: Submit this form at the completion of each cycle of salvage treatment. Dates are to be recorded as mm-dd-yyyy unless otherwise specified

Ähnliche Modelle

Kontakt

Hilfe